CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue	$ 331,339	$ 391,866	$ 336,794
Expenses:
Selling, general and administrative	63,538	16,187	13,883
Research and development	41,432	576	1,788
Amortization of acquired intangible assets	5,581	0	0
Gain on sale of Theravance Respiratory Company, LLC ("TRC")	(266,696)	0	0
Loss on extinguishment of debt	20,662	0	0
Changes in fair values of equity method investments, net	161,749	(84,392)	(49,511)
Changes in fair value of other equity and long-term investments, net	(8,462)	(6,638)	(766)
Interest and dividend income	(6,369)	(1,839)	(1,524)
Interest expense	15,789	19,070	18,331
Other expense, net	3,373	3,626	348
Total expenses	44,390	(53,410)	(17,451)
Income before income taxes	286,949	445,276	354,245
Income tax expense, net	66,687	76,439	60,431
Net income	220,262	368,837	293,814
Net loss attributable to noncontrolling interests	6,341	102,983	69,412
Net income attributable to Innoviva stockholders	$ 213,921	$ 265,854	$ 224,402
Basic net income per share attributable to Innoviva stockholders	$ 3.07	$ 3.24	$ 2.21
Diluted net income per share attributable to Innoviva stockholders	$ 2.37	$ 2.87	$ 2.02
Shares used to compute Innoviva basic and diluted net income per share:
Shares used to compute basic net income per share	69,644	82,062	101,320
Shares used to compute diluted net income per share	95,248	94,310	113,554
Royalty revenue from a related party
Revenue:
Total revenue	$ 311,645	$ 391,866	$ 326,794
Revenue from collaborative arrangements
Revenue:
Total revenue	0	0	10,000
Net product sales
Revenue:
Total revenue	19,694	0	0
Expenses:
Cost of products sold (inclusive of amortization of inventory fair value adjustments and excluding amortization of acquired intangible assets)	$ 13,793	$ 0	$ 0